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The recent emergence of B.1.1.529, the Omicron variant1,2, has raised concerns of
escape from protection by vaccines and therapeutic antibodies. A key test for
potential countermeasures against B.1.1.529 is their activity in preclinical rodent
models of respiratory tract disease. Here, using the collaborative network of the
SARS-CoV-2 Assessment of Viral Evolution (SAVE) programme of the National Institute
of Allergy and Infectious Diseases (NIAID), we evaluated the ability of several B.1.1.529
isolates to cause infection and disease in immunocompetent and human ACE2
(hACE2)-expressing mice and hamsters. Despite modelling data indicating that
B.1.1.529 spike can bind more avidly to mouse ACE2 (refs. 3,4), we observed less
infection by B.1.1.529 in 129, C57BL/6, BALB/c and K18-hACE2 transgenic mice than by
previous SARS-CoV-2 variants, with limited weight loss and lower viral burden in the
upper and lower respiratory tracts. In wild-type and hACE2 transgenic hamsters, lung
infection, clinical disease and pathology with B.1.1.529 were also milder than with
historical isolates or other SARS-CoV-2 variants of concern. Overall, experiments from
the SAVE/NIAID network with several B.1.1.529 isolates demonstrate attenuated lung
disease in rodents, which parallels preliminary human clinical data.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused
a pandemic resulting in millions of deaths worldwide. The extensive morbidity and mortality made the development of vaccines, antibody-based
countermeasures and antiviral agents a global health priority. As part of
this process, several models of SARS-CoV-2 infection and lung pathogenesis were developed in animals for rapid testing5. Remarkably, several
highly effective vaccines and therapeutics were deployed with billions
of doses given worldwide. Although these measures markedly reduced
hospitalizations and deaths, their efficacy has been jeopardized by the
emergence of SARS-CoV-2 variants with mutations in the spike gene.
The SARS-CoV-2 spike protein engages angiotensin-converting
enzyme 2 (ACE2) on the surface of human cells to facilitate entry and
infection of cells6. Upon cell attachment, spike proteins are cleaved
by host proteases into S1 and S2 fragments. The S1 protein includes

the amino-terminal (NTD) and receptor-binding (RBD) domains.
The RBD is the target of many potently neutralizing monoclonal7–11 and
serum polyclonal12 antibodies. Although SARS-CoV-2 spike proteins
from strains early in the pandemic bound to ACE2 from several animal
species (for example, hamster, ferret and nonhuman primates), they
did not bind mouse ACE2, which explained why laboratory strains of
mice could not be infected by SARS-CoV-2 (refs. 6,13); indeed, mice could
become susceptible through expression of hACE2 via a transgene14–16
or viral vector17,18, or under regulation of the mouse ACE2 promoter19–21.
Later in the pandemic, several strains acquired a mouse-adapting spike
substitution (N501Y), which allowed engagement of mouse ACE2 and
productive infection of mice without hACE2 expression22–24.
In late November 2021, the Omicron (B.1.1.529) variant emerged.
This variant has the largest number (>30) of substitutions, deletions
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Fig. 1 | B.1.1.529 is less pathogenic in mice. a, Left: weight change in
mock-infected mice (n = 4) or mice inoculated with B.1.1.529 + A701V (n = 5),
B.1.1.529 (n = 3) or B.1.351 (n = 3). Middle: weight change in mice inoculated with
B.1.1.529 or B.1.351 (n = 5) (**P = 0.0075, ***P = 0.0006, ****P < 0.0001). Right:
weight change in mice inoculated with B.1.1.529 (n = 4), B.1.1.7 (n = 10) or B.1.351
(n = 18). Comparison between B.1.351 and B.1.1.529: *P = 0.0151, ***P = 0.0003
(3 dpi) and 0.0006 (4 dpi). Mean ± s.e.m. b, Viral RNA level in mice inoculated
with B.1.1.529 or B.1.351 (n = 5) (**P = 0.0079). c, Infectious virus titre in mice
inoculated with B.1.1.529 + A701V, B.1.1.529 or B.1.351 (n = 3). d, Infectious
virus titre in mice inoculated with B.1.1.529 or B.1.351 (n = 5) (**P = 0.0079).
e, Pulmonary function analysis as measured by whole-body plethysmography.
Mean ± s.e.m. Comparison between B.1.617.2 and B.1.351: **P = 0.0095 (n = 5
each). f, Left, weight change in mice inoculated with WA1/2020 D614G (103
FFU; n = 6), B.1.1.529 (103 FFU; n = 3), B.1.1.529 (104 PFU; n = 6) or B.1.1.529 (105

FFU; n = 3). Right, weight change in mice inoculated with 104 PFU of B.1.1.529
+A701V (n = 6) or B.1.351 (n = 6), or mock-infected, age-matched mice (n = 4).
Mean ± s.e.m. g, Infectious virus titre in lungs of mice inoculated with
WA1/2020 D614G (n = 8) or B.1.1.529 (n = 7) (****P < 0.0001). h, Infectious virus
titre in mice inoculated with B.1.1.529 + A701V or B.1.351 (n = 3). i, Heat map of
concentration of cytokines and chemokines in lungs of infected mice. Results
are from one (a–f, h, i) or two (g) experiments. The dotted line is the limit of
detection. Statistical analysis (a, e: two-way analysis of variance (ANOVA) with
multiple comparisons test; b, d, g: two-tailed Mann–Whitney test) was
performed on datasets with four or more data points. See Supplementary
Table 1 for more information. CCL4, chemokine (C-C motif) ligand 4; IL-18,
interleukin-18; CXCL2, chemokine (C-X-C motif) ligand 2; TNF, tumour necrosis
factor; GM-CSF, granulocyte–macrophage CSF; IFNγ, interferon-γ.

or insertions in the spike protein described so far, raising concerns
of escape from protection by vaccines and therapeutic monoclonal
antibodies. B.1.1.529 isolates have many changes in the RBD (G339D,
R346K, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K,
E484A, Q493R, G496S, Q498R, N501Y and Y505H). The N501Y substitution along with changes at sites (K417, E484, Q493, Q498 and N501)
associated with mouse adaptation25–30 indicated that B.1.1.529 should
infect mice3. One study speculated that the progenitor of B.1.1.529
jumped from humans to mice, and then back into humans4. In support
of this, B.1.1.529 RBD binds to mouse ACE2 (ref. 31). Last, hamsters have
been a valuable animal model for assessing countermeasures against
SARS-CoV-2 and variants. Hamsters are susceptible to SARS-CoV-2 infection and show similar pathological changes to those seen in lung tissues

from COVID-19 patients5,32,33. Here, using data from several laboratories
of the SAVE/NIAID consortium (Supplementary Table 1), we report on
the infectivity of several B.1.1.529 isolates in mice and hamsters, two
key rodent models of SARS-CoV-2 infection and pathogenesis.
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B.1.1.529 infection in mice
Because of the presence of several amino acid alterations that are
considered mouse adapting, we predicted that B.1.1.529 should infect
immunocompetent mice and cause lung disease as seen with other
recombinant strains (WA1/2020 N501Y) or variants (for example,
B.1.351) containing N501Y substitutions. We first tested B.1.1.529 in 129
mice. Two of our laboratories independently inoculated 6–8-week-old
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Fig. 2 | B.1.1.529 is less pathogenic in wild-type and hACE2-transgenic
Syrian hamsters. a, Weight change in uninfected age-matched hamsters (n = 3)
or in hamsters inoculated with B.1.1.529 or B.1.617.2 (n = 4). Mean ± s.e.m.
b, Weight change in uninfected age-matched hamsters (n = 9) or in hamsters
inoculated with B.1.1.529 (n = 10) or WA1/2020 D614G (n = 6). Mean ± s.e.m.
(red, *P = 0.0293; red, **P = 0.0046 and 0.0014; black, **P = 0.0021; black,
***P = 0.0001). c, Weight change in hamsters inoculated with 103, 104, 105 or 106
PFU of B.1.1.529 or 103 PFU of B.1.617.2 (n = 4). Mean ± s.e.m. Comparison
between B.1.617.2 and B.1.1.529 (103 PFU): *P = 0.0476, **P = 0.0041, 0.0041,
0.0047 and 0.0019, respectively. d, Weight change in hamsters inoculated with
B.1.1.529 (n = 5) or WA1/2020 (n = 9). Mean ± s.e.m. (****P < 0.0001). e, Viral RNA
level in hamsters inoculated with WA1/2020 D614G or B.1.1.529 (n = 15)
(*P = 0.015, ***P < 0.0003). f, Infectious virus titre in hamsters inoculated with
B.1.617.2 or B.1.1.529 (n = 4) (*P = 0.0286; NS, not significant). g, Nasal wash viral
RNA level in hamsters inoculated with WA1/2020 (n = 8) or B.1.1.529 (n = 3).
TCID50, median tissue culture infectious dose. h, Pulmonary function analysis
by whole-body plethysmography. Mean ± s.e.m. (Penh and Rpef, comparison

between B.1.617.2 and B.1.1.529: *P = 0.0263 (3 dpi), *P = 0.0186 (5 dpi),
***P = 0.0005 (7 dpi), ****P < 0.0001) (n = 4). i, Micro-CT images of the lungs of
mock-infected (n = 3) or B.1.617.2- (n = 4) and B.1.1.529-infected (n = 4) hamsters
at 7 dpi. Multifocal nodules (black arrows), ground-glass opacity (white
arrowheads) and pneumomediastinum (white asterisk) are indicated. j, CT
score for uninfected hamsters (n = 3) or those inoculated with B.1.617.2 or
B.1.1.529 (n = 4) (****P < 0.0001). k, Weight change in hACE2 hamsters
inoculated with HP-095 D614G or B.1.1.529 (n = 4). Error bars indicate s.e.m.
l, Survival of hACE2 hamsters after inoculation with HP-095 D614G or B.1.1.529
(n = 4) (*P = 0.029). m, Infectious virus titre of hACE2 hamsters inoculated with
HP-095 D614G or B.1.1.529; n = 3 (3 dpi), n = 4 (5 dpi) (*P = 0.0286). The results
are from one (a, c, d, f–m) or two to three independent (b, e) experiments.
Dotted lines represent the limit of detection. Statistical analysis (b–d, h:
two-way ANOVA with multiple comparisons test; e, j: two-tailed t-test, f, m:
two-tailed Mann–Whitney test, l: log-rank test) was performed on datasets with
four or more data points. See Supplementary Table 1 for more information.

or 10–20-week-old 129 mice with 104, 105 or 106 infectious units
(plaque-forming units (PFU) or focus-forming units (FFU)) of three
different B.1.1.529 strains (Supplementary Tables 1 and 2). As 129 mice
sustain 10 to 15% loss of body weight 3 to 4 days post infection (dpi) yet
recover and gain weight beginning at 5 dpi (refs. 22,34) with SARS-CoV-2

strains encoding N501Y substitutions34, we assessed weight change with
B.1.1.529 at 3 and 4 dpi. However, after inoculation with B.1.1.529, 129
mice failed to lose weight (Fig. 1a). Similarly, aged (10- to 14-month-old)
C57BL/6 mice also did not lose weight after B.1.1.529 infection, whereas
those infected with B.1.351 did (Fig. 1a).
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We next compared viral burden in B.1.1.529- and B.1.351-infected 129
mice. At 3 dpi, 129 mice infected with B.1.351 sustained high levels of infection in the nasal wash, nasal turbinates and lungs (Fig. 1b). The levels of
viral RNA in the nasal turbinates and lungs of B.1.1.529-infected mice were
10- to 100-fold lower than those in B.1.351-infected animals (Fig. 1b). Similar results were seen in a separate cohort of 129 mice at 4 dpi, with 1,000- to
100,000-fold less infectious virus recovered from nasal turbinates and
lungs of animals infected with B.1.1.529 compared to B.1.351 (Fig. 1c).
Members of the group also tested B.1.1.529 in BALB/c mice. At 2 dpi,
infectious virus levels in the nasal turbinates and lungs were significantly
lower (≈1,000-fold, P < 0.001) in BALB/c mice infected with B.1.1.529
compared to B.1.351 (Fig. 1d). We used whole-body plethysmography35 to
measure pulmonary function in infected mice. At 2 dpi, whereas B.1.351
caused an increase (P < 0.001) in the lung enhanced pause (Penh), a
marker of bronchoconstriction, B.1.1.529 did not (Fig. 1e). The ratio of
peak expiratory flow (Rpef) also was decreased at 2 dpi in BALB/c mice
infected with B.1.351 but not B.1.1.529 (P < 0.001, Fig. 1e).
Two of our groups tested B.1.1.529 infection in K18-hACE2 transgenic mice, which express hACE2 under an epithelial cytokeratin
promoter14, and are more susceptible to SARS-CoV-2 infection16. At
intranasal doses ranging from 103 to 105 infectious units of B.1.1.529,
weight loss was not observed over the first 5 to 6 days of infection
in younger or older K18-hACE2 mice (Fig. 1f). These data contrast
with historical results with WA1/2020 D614G or variant (for example,
B.1.351) SARS-CoV-2 strains16,24,34,36, which uniformly induce weight
loss starting at 4 dpi. The groups separately observed reduced levels
690 | Nature | Vol 603 | 24 March 2022

of infectious B.1.1.529 compared to WA1/2020 D614G or B.1.351 in
the lower respiratory tracts at 3 dpi (Fig. 1g, h). Finally, we assessed
inflammatory responses in the lungs of K18-hACE2 mice at 3 dpi. Mice
inoculated with B.1.1.529 had lower levels of several pro-inflammatory
cytokines and chemokines compared to those inoculated with B.1.351,
with many values similar to those of uninfected controls (Fig. 1i and
Supplementary Table 3). Thus, on the basis of several parameters
(weight change, viral burden, respiratory function measurements
and cytokine responses), B.1.1.529 seems attenuated in the respiratory tract of several strains of mice.

B.1.1.529 infection in hamsters
Four members of our group tested three different B.1.1.529 strains for their
ability to infect and cause disease (Supplementary Table 1). Whereas intranasal infection with historical or other variant SARS-CoV-2 strains generally resulted in ≈10 to 15% reduction in body weight over the first week, we
observed no weight loss in hamsters inoculated with B.1.1.529 (Fig. 2a–d),
although animals did not gain body weight as rapidly as uninfected hamsters. Viral RNA analysis at 4 dpi showed lower levels of B.1.1.529 infection
in the lungs (12-fold, P < 0.001) compared to WA1/2020 D614G (Fig. 2e). A
comparison of infectious viral burden in tissues at 3 dpi between B.1.617.2
and B.1.1.529 strains showed virtually no difference in nasal turbinates
but substantially less infection of B.1.1.529 in the lungs of most animals
(Fig. 2f). A comparison of viral RNA levels between WA1/2020 and B.1.1.529
in nasal washes at 4 dpi did not show substantial differences in titres

(Fig. 2g). Thus, in hamsters infected with B.1.1.529, the upper, but not
the lower, respiratory tract infection seems relatively intact.
We used whole-body plethysmography to measure pulmonary
function in infected Syrian hamsters. Starting at 3 dpi and continuing until 7 dpi, infection with B.1.617.2 caused an increase (P < 0.05) in
the Penh, whereas B.1.1.529 infection did not (Fig. 2h, left). The Rpef
was decreased at 5 and 7 dpi in animals infected with B.1.617.2 but not
B.1.1.529 (P < 0.001; Fig. 2h, middle). Finally, hamsters infected with
B.1.617.2, but not B.1.1.529, demonstrated a decrease in respiratory
rate (frequency) compared to uninfected animals (Fig. 2h, right). On
the basis of several functional parameters, lung infection and disease
after B.1.1.529 infection was attenuated compared to that after infection with other variant strains.
We performed microcomputed tomography (micro-CT) to assess for
lung abnormalities in hamsters at 7 dpi. Micro-CT analysis revealed lung
abnormalities in all B.1.617.2-infected hamsters on 7 dpi that were consistent with commonly reported imaging features of COVID-19 pneumonia37.
In comparison, analysis of B.1.1.529-infected hamsters on 7 dpi revealed
patchy, ill-defined ground-glass opacity consistent with minimal to mild
pneumonia. Syrian hamsters infected with B.1.617.2 had a much higher
CT disease score35 than those infected with B.1.1.529 (Fig. 2i, j).
Members of our group also compared lung pathology in Syrian hamsters after infection with B.1.617.2 or B.1.1.529. The lungs
obtained from B.1.617.2-infected hamsters showed congestion and/
or haemorrhage, which were absent in B.1.1.529-infected animals
(Fig. 3a). Immune cell infiltration and inflammation were present in
the peribronchial regions of the lungs at 3 dpi with B.1.617.2. At 6 dpi,
extensive infiltration of neutrophils and lymphocytes in the alveolar
space was accompanied by pulmonary edema and haemorrhage
(Fig. 3b, inset), and regenerative changes in the bronchial epithelia
became prominent (Fig. 3b). By contrast, in B.1.1.529-infected hamsters, small foci of inflammation in the alveoli and peribronchial
regions were observed only at 6 dpi (Fig. 3b). A worse histopathology
score of viral pneumonia at 6 dpi was measured after B.1.617.2 than
B.1.1.529 infection (Fig. 3c). After B.1.617.2 infection, viral RNA was
detected readily in the alveoli and bronchial epithelia at 3 and 6 dpi
(Fig. 3d). After B.1.1.529 infection, fewer bronchial epithelial cells and
alveoli were positive for viral RNA at either time point (Fig. 3d). Thus,
B.1.1.529 replicates less efficiently in the lungs of Syrian hamsters,
which results in less severe pneumonia compared to that resulting
from the B.1.617.2 variant.
Although hamster ACE2 can serve as a receptor for the SARS-CoV-2
spike protein, some of the contact residues in hACE2 are not conserved38, which could diminish infectivity. To develop a more susceptible hamster model, members of the consortium used transgenic
hamsters expressing hACE2 under the epithelial cytokeratin-18 promoter39. Whereas intranasal inoculation of 103 PFU of HP-095 D614G
virus resulted in marked weight loss within the first week (Fig. 2k)
and uniform mortality by 10 dpi (Fig. 2l), less weight loss and death
(P < 0.05) were observed after infection with B.1.1.529. Moreover,
1,000- to 10,000-fold lower levels of infectious virus were measured
in the lungs of hACE2 transgenic hamsters challenged with B.1.1.529
than in those challenged with HP-095 D614G at 3 and 5 dpi (Fig. 2m).
As seen in wild-type Syrian hamsters, smaller differences in infection
were observed in the nasal turbinates. Thus, B.1.1.529 infection in the
lung is attenuated in both wild-type and hACE2 transgenic hamsters.

Discussion
Our experiments indicate that the B.1.1.529 variant is less pathogenic
in laboratory mice and hamsters. Although these results are consistent
with preliminary data in humans40,41, the basis for attenuation remains
unknown. One study indicates that B.1.1.529 replicates faster in the
human bronchus and less in lung cells, which may explain its greater
transmissibility and putative lower disease severity42. We observed

that B.1.1.529 resulted in a lower level of infection of hamster bronchial
cells in vivo and lower viral burden in nasal washes and turbinates in
mice compared with other SARS-CoV-2 strains. The attenuation in mice
was unexpected given that B.1.1.529 has alterations in the RBD that
are sites associated with adaptation for mice25–27. The attenuation in
hamsters seen by our group and others43 was also surprising, given that
other SARS-CoV-2 variants replicate to high levels in this animal35,44,45.
Whereas the >30 changes in the B.1.1.529 spike protein could impact
receptor engagement, changes in other proteins could affect replication, temperature sensitivity, cell and tissue tropism, and induction of
pro-inflammatory responses in a species-specific manner. Our results
showing attenuated B.1.1.529 infection in laboratory mice do not support the suggestion that B.1.1.529 has a mouse origin4. However, infection studies in wild mice46 are needed to fully address this question.
Although B.1.1.529 is less pathogenic in mice and hamsters, these
animals still will have utility in evaluating vaccine, antibody or
small-molecule inhibitors. The mice and hamsters tested, to varying
degrees, showed evidence of viral replication and dissemination to
the lower respiratory tract, which could be mitigated by countermeasures. The most severe B.1.1.529 infection and disease was observed in
hACE2-expressing mice and hamsters, which is consistent with findings for other SARS-CoV-2 strains16,24,39,47, and possibly related to the
enhanced interactions between hACE2 and B.1.1.529 spike48. Indeed,
structural analysis of the B.1.1.529 spike protein in complex with hACE2
reveals new interactions formed by mutated residues in the RBD48,49.
These in vivo studies were performed as part of the SAVE/NIAID consortium and reflect a network that communicates weekly to expedite
progress on SARS-CoV-2 variants. This format had several advantages:
animal experiments were reproduced across laboratories providing
confidence in results; several B.1.1.529 isolates were tested limiting
the possibility of sequence adaptations in a strain from one laboratory that could skew results; several strains of mice and hamsters at
different ages were tested allowing for a comprehensive dataset; and
the groups used overlapping metrics to evaluate infection and disease
in the different animal models.
We note several limitations to our study. First, our experiments reflect
data from a consortium that did not use uniform study design and metrics, which created variability in outcomes; despite this, data from several
groups indicate that B.1.1.529 is attenuated in rodent models. Second,
although attenuation of B.1.1.529 in mice and hamsters correlates with
preliminary data in humans, evaluation in nonhuman primates and
unvaccinated, previously uninfected humans is needed for corroboration. Third, we used the prevailing B.1.1.529 isolate that lacks an R346K
substitution. Approximately 10% of B.1.1.529 sequences in GISAID as
of the writing of this paper have an R346K sequence, and this substitution or others in gene products apart from spike might affect virulence.
Although one of the B.1.1.529 isolates we tested contains an additional
A701V change in spike near the furin cleavage site, it was still attenuated
in mice. Fourth, detailed pathological and immunological analyses were
not performed for all of the animal species studied. It remains possible
that B.1.1.529 is attenuated clinically (for example, weight loss) because
of defects in promoting pathological host responses.
In summary, our collective studies rapidly and reproducibly demonstrated attenuated infection in several strains of mice and hamsters.
Experiments are ongoing to determine the basis for attenuation in mice
and hamsters and to determine how this relates to B.1.1.529 infection
in humans.
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Methods
Cells
Vero-TMPRSS2 (refs. 35,50,51) and Vero-hACE2-TMPRSS2 (ref. 52) cells were
cultured at 37 °C in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 10 mM HEPES pH 7.3 and
100 U ml−1 penicillin–streptomycin. Vero-TMPRSS2 cells were supplemented with 5 μg ml−1 blasticidin or 1 mg ml−1 geneticin (depending on
the cell line) and in some cultures with Plasmocin. Vero-hACE2-TMPRSS2
cells were supplemented with 10 µg ml−1 puromycin. All cells routinely
tested negative for mycoplasma using a PCR-based assay.
Viruses
The WA1/2020 recombinant strains with substitutions (D614G and/
or N501Y/D614G) were described previously53. The B.1.1.529 isolates
(hCoV-19/USA/WI-WSLH-221686/2021 (GISAID: EPI_ISL_7263803),
hCoV-19/Japan/NC928-2N/2021 (NC928) (GISAID: EPI_ISL_7507055),
hCoV-19/USA/NY-MSHSPSP-PV44476/2021 (GISAID: EPI_ISL_7908052),
hCoV-19/USA/NY-MSHSPSP-PV44488/2021 (GISAID: EPI_ISL_7908059)
and hCoV-19/USA/GA-EHC-2811C/2021 (GISAID: EPI_ISL_7171744)) were
obtained from nasal swabs and passaged on Vero-TMPRSS2 cells as
described previously33,35,51. Sequence differences between B.1.1.529
isolates are depicted in Supplementary Table 2. Other viruses used
included: SARS-CoV-2/UT-HP095-1N/Human/2020/Tokyo (HP-095;
D614G), hCoV-19/USA/CA_CDC_5574/2020 (Alpha, B.1.1.7; BEI NR54011),
hCoV-19/USA/MD-HP01542/2021 (Beta, B.1.351), 20H/501Y.V2 (Beta,
B.1.351), hCoV-19/USA/PHC658/202 (Delta, B.1.617.2) and hCoV-19/
USA/WI-UW-5250/2021 (Delta, B.1.617.2; UW-5250)54. All viruses were
subjected to next-generation sequencing as described previously55 to
confirm the stability of substitutions and avoid introduction of adventitious alterations All virus experiments were performed in an approved
biosafety level 3 facility.
Animal experiments and approvals
Animal studies were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of
the National Institutes of Health. The protocols were approved by the
Institutional Animal Care and Use Committee at the Washington University School of Medicine (assurance number A3381–01), University
of Wisconsin, Madison (V006426), St Jude Children’s Research Hospital
(assurance number D16-00043), Emory University, University of Iowa
(assurance number A3021-01), Icahn School of Medicine at Mount
Sinai (PROTO202100007), BIOQUAL, Inc., and the Animal Experiment Committee of the Institute of Medical Science, the University
of Tokyo (approval numbers PA19-72 and PA19-75). Virus inoculations
were performed under anaesthesia that was induced and maintained
with ketamine hydrochloride and xylazine, and all efforts were made to
minimize animal suffering. In vivo studies were not blinded, and animals
were randomly assigned to infection groups. No sample-size calculations were performed to power each study. Instead, sample sizes were
determined based on previous in vivo virus challenge experiments.
Mouse infection experiments
Heterozygous K18-hACE2 C57BL/6J mice (strain 2B6.Cg-Tg
(K18-ACE2)2Prlmn/J), 129 mice (strain 129S2/SvPasCrl or 129S1/SvImJ)
and C57BL/6 (strain 000664) mice were obtained from The Jackson
Laboratory and Charles River Laboratories. BALB/c mice were purchased from Japan SLC Inc. Animals were housed in groups and fed
standard chow diets. Infection experiments were performed as follows. In a first set of experiments, 5-month-old female K18-hACE2 mice
were inoculated intranasally with 103, 104 or 105 FFU of SARS-CoV-2.
In a second set of experiments, 129S1 male and female mice were
used between 10 and 20 weeks of age. Mice were anaesthetized with
isoflurane and inoculated intranasally with virus (50 μl, 106 PFU per
mouse). In a third set of experiments, 6-week-old female BALB/c mice

were inoculated intranasally with 105 PFU of hCoV-19/Japan/NC9282N/2021 or hCoV-19/USA/MD-HP01542/2021. In a fourth set of experiments, retired breeder female C57BL/6 mice (10 to 14 months old) were
anaesthetized with ketamine–xylazine and inoculated intranasally
with SARS-CoV-2 in a total volume of 50 μl DMEM. Animal weight and
health were monitored daily. In a fifth set of experiments, 6–8-week-old
female 129S1 mice and 6-month-old female K18-hACE2 mice were inoculated intranasally under light ketamine–xylazine sedation with 104
PFU of hCoV-19/USA/NY-MSHSPSP-PV44476/2021 or hCoV-19/USA/
NY-MSHSPSP-PV44488/2021 in a total volume of 50 μl.

Hamster infection experiments
Male 5–6-week-old Syrian golden hamsters were obtained from Charles
River Laboratories, Envigo or Japan SLC Inc. The K18-hACE2 transgenic
hamster line was developed with a piggyBac-mediated transgenic
approach, in which the K18-hACE2 cassette from the pK18-hACE2 plasmid14 was transferred into a piggyBac vector, pmhyGENIE-3 (ref. 56), for
pronuclear injection. hACE2 transgenic hamsters will be described
in detail elsewhere39. Female 12-month-old transgenic animals were
used. Infection experiments were performed as follows. In a first set
of experiments, animals were challenged intranasally with 103 PFU of
WA1/2020 D614G or B.1.1.529 variant in 100 µl. In a second set of experiments, under isoflurane anaesthesia, wild-type Syrian hamsters were
intranasally inoculated with 103 PFU of SARS-CoV-2 strains in 30 µl.
Body weight was monitored daily. For virological and pathological
examinations, four hamsters per group were euthanized at 3 and
6 dpi, and nasal turbinates and lungs were collected. The virus titres
in the nasal turbinates and lungs were determined by plaque assays on
Vero-TMPRSS2 cells. Human ACE2 transgenic hamsters were intranasally inoculated with 103 PFU of HP-095 D614G or B.1.1.529 (hCoV-19/
USA/WI-WSLH-221686/2021) in 50 µl. Body weight and survival were
monitored daily, and nasal turbinates and lungs were collected at 3 and
5 dpi for virological analysis. In a third set of experiments, six-week-old
male Syrian golden hamsters were randomized into groups of 4 to 6
and inoculated with SARS-CoV-2 via delivery of 100 µl of appropriately diluted virus in PBS equally split between both nostrils. Weight
change and clinical observations were collected daily. In a fourth set of
experiments, while under isoflurane anaesthesia, male 8–10-week-old
hamsters were inoculated intranasally with 104 PFU of WA1/2020 or
B.1.1.529 in 100 µl volume. Body weight and survival were monitored
daily. Nasal washes were taken at 4 dpi for virological analysis.
Measurement of viral burden
Mouse studies. Tissues were weighed and homogenized with zirconia
beads in a MagNA Lyser instrument (Roche Life Science) in 1,000 μl
DMEM medium supplemented with 2% heat-inactivated FBS. Tissue
homogenates were clarified by centrifugation at 10,000 r.p.m. for 5 min
and stored at −80 °C. RNA was extracted using the MagMax mirVana
Total RNA isolation kit (Thermo Fisher Scientific) on the Kingfisher Flex
extraction robot (Thermo Fisher Scientific). Viral RNA (N gene) was
reverse transcribed and amplified using the TaqMan RNA-to-CT 1-Step
Kit (Thermo Fisher Scientific), and data were analysed and normalized
as described previously57. Infectious virus titres were determined by
plaque assay on Vero-hACE2-TMPRSS2 cells as previously published24.
The viral titres in the nasal turbinates and lungs were determined by
plaque assay on Vero-TMPRSS2 cells as previously published51. At the
indicated day post infection, mice were euthanized with isoflurane
overdose and one lobe of lung tissue was collected in an Omni Bead
ruptor tube filled with Tri Reagent (Zymo, number R2050-1-200).
Tissue was homogenized using an Omni Bead Ruptor 24 (5.15 ms, 15 s),
and then centrifuged to remove debris. RNA was extracted using a
Direct-zol RNA MiniPrep Kit (Zymo, number R2051), and then converted to cDNA using a High-capacity Reverse Transcriptase cDNA Kit
(Thermo, number 4368813). SARS-CoV-2 RNA-dependent RNA polymerase and subgenomic RNA were measured as described previously29,58.
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The subgenomic SARS-CoV-2 RNA levels were quantified in nasal turbinates and lungs by quantitative PCR with reverse transcription as
previously published29,55. Infectious virus titres in nasal turbinates
and lungs were determined by plaque assay on Vero-TMPRSS2 cells as
described previously59.
Hamster studies. Lungs were collected 4 dpi and homogenized in
1.0 ml of DMEM, clarified by centrifugation (1,000 g for 5 min) and
stored at −80 °C. Nasal washes were clarified by centrifugation (2,000 g
for 10 min) and the supernatant was stored at −80 °C. To quantify viral
load in lung tissue homogenates and nasal washes, RNA was extracted
from 100 µl samples using E.Z.N.A. Total RNA Kit I (Omega) and eluted
with 50 µl of water. Four microlitres of RNA was used for real-time quantitative PCR with reverse transcription to detect and quantify the N gene
of SARS-CoV-2 using TaqMan RNA-to-CT 1-Step Kit (Thermo Fisher Scientific) as described previously60. The virus titres in the nasal turbinates
and lungs were determined by plaque assay on Vero E6 cells expressing
human TMRPSS2 as previously published61. RNA was extracted from
clarified nasal washes using the Qiagen RNeasy extraction kit (Qiagen)
following the manufacturer’s instructions. Samples were purified on
the included columns and eluted in 50 µl of nuclease-free water. PCR
was conducted using 4× TaqMan Fast Virus Master Mix (Thermo Fisher)
and an N-gene primer/probe set.

Plaque assay
Vero-TMPRSS2 or Vero-TMPRSS2-hACE2 cells were seeded at a density
of 1 × 105 cells per well in 24-well tissue culture plates. The following
day, medium was removed and replaced with 200 μl of material to be
titrated diluted serially in DMEM supplemented with 2% FBS. One hour
later, 1 ml of methylcellulose overlay was added. Plates were incubated
for 72 h, and then fixed with 4% paraformaldehyde (final concentration)
in PBS for 20 min. Plates were stained with 0.05% (w/v) crystal violet
in 20% methanol and washed twice with distilled, deionized water.
Measurement of cytokines and chemokines
Superior and middle lobes of the lungs from K18-hACE2 mice
(mock-infected or 3 dpi) were collected, homogenized and then
stored at −80 °C. After thawing, lung homogenates were centrifuged
at 10,000g for 5 min at 4 °C. Samples were inactivated with ultraviolent light in a clear, U-bottom 96-well plate (Falcon). A mouse 26-plex,
bead-based Luminex assay (catalogue number EPXR260-26088-901)
was used to profile cytokine and chemokine levels in clarified lung
supernatants. The assay was performed according to the manufacturer’s instructions, and all incubation steps occurred on an orbital
shaker set at 300 r.p.m. Briefly, 50 μl of clarified lung homogenate
supernatant was combined with beads in a lidded, black 96-well plate
supplied as part of the kit and incubated for 30 min at room temperature, and then overnight at 4 °C. The next day, the plate was allowed
to equilibrate to room temperature for 30 min, washed 3 times with
150 μl per well of 1× wash buffer diluted, and then 25 μl per well of 1×
detection antibody mixture was added for 30 min at room temperature.
The plate was washed 3 times, and then 50 μl per well of 1× Streptavidin–PE solution was added for 30 min at room temperature. After
washing 3 times, 120 μl per well of reading buffer was added, and the
plate was incubated for 5 min at room temperature. Data were acquired
on a Luminex 100/200 analyser (Millipore) with xPONENT software
(version 4.3) and analysed using GraphPad Prism (version 8.0) and R
(version 4.0.5).
Micro-CT imaging
Hamsters were inoculated intranasally with 103 PFU (in 30 μl) of B.1.1.529
(strain NC928), B.1.617.2 (UW-5250) or PBS. Lungs of the infected animals were imaged by using an in vivo micro-CT scanner (CosmoScan
FX; Rigaku Corporation). Under ketamine–xylazine anaesthesia, the
animals were placed in the image chamber and scanned for 2 min at

90 kV, 88 μA, field of view 45 mm and pixel size 90.0 μm. After scanning, the lung images were reconstructed by using the CosmoScan
Database software of themicro-CT (Rigaku Corporation) and analysed
by using the manufacturer-supplied software. A CT severity score,
adapted from a human scoring system, was used to grade the severity
of the lung abnormalities62. Each lung lobe was analysed for degree of
involvement and scored from 0 to 4 depending on the severity: 0 (none,
0%), 1 (minimal, 1%–25%), 2 (mild, 26%–50%), 3 (moderate, 51%–75%) or
4 (severe, 76%–100%). Scores for the five lung lobes were summed to
obtain a total severity score of 0–20, reflecting the severity of abnormalities across the three infected groups. Images were anonymized and
randomized; the scorer was blinded to the group allocation.

Pathology
Excised animal tissues were fixed in 4% paraformaldehyde in PBS, and
processed for paraffin embedding. The paraffin blocks were cut into
3-µm-thick sections and mounted on silane-coated glass slides. Sections were processed for in situ hybridization using an RNA scope 2.5
HD Red Detection kit (Advanced Cell Diagnostics) with an antisense
probe targeting the nucleocapsid gene of SARS-CoV-2 (Advanced Cell
Diagnostics). Lung tissue sections were scored for pathology on the
basis of the percentage of alveolar inflammation in a given area of a
pulmonary section collected from each animal in each group using
the following scoring system: 0, no pathological change; 1, affected
area (≤10%); 2, affected area (<50%, >10%); 3, affected area (≥50%); an
additional point was added when pulmonary edema and/or alveolar
haemorrhage was observed.
Reagent availability
All reagents described in this paper are available through material
transfer agreements.
Statistical analysis
The number of independent experiments and technical replicates
used are indicated in the relevant figure legends. Statistical analysis
included unpaired t-tests, Mann–Whitney tests and ANOVA with multiple correction post tests.
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this paper.

Data availability
All data supporting the findings of this study are available in the paper.
There are no restrictions in obtaining access to primary data. Source
data are provided with this paper.
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